SCHEMBL30528203

SCHEMBL30528203

CC(C)[Si](OCc1ccc(N)c(N[C@@H]2CCCCN(C(=O)OC(C)(C)C)C2)c1)(C(C)C)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 5/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC2 Q92769 2/20 0.40
▸ PARP1 P09874 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ BTK Q06187 2/20 0.37
▸ PIM1 P11309 2/20 0.36
▸ PIM2 Q9P1W9 2/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ BACE1 P56817 2/20 0.36
▸ CTSD P07339 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25404464 0.89 GFER (0.36) HDAC1HDAC2
SCHEMBL25404455 0.89 GFER (0.36) HDAC1HDAC2
SCHEMBL30528198 0.87 USP30 (0.39) USP30BRD4NPC1ALDH1A1MAPT
SCHEMBL26584991 0.86 USP30 (0.46) USP30BRD4HDAC1HDAC2PARP1
SCHEMBL25215488 0.80 USP30 (0.48) USP30BRD4HDAC1HDAC2PARP1
SCHEMBL30461616 0.80 USP30 (0.48) USP30BRD4HDAC1HDAC2PARP1
SCHEMBL30528200 0.78 OPRM1 (0.38) BTKBACE1CTSD
SCHEMBL25219095 0.77 USP30 (0.49) USP30HDAC1HDAC2PARP1BTK
SCHEMBL30461693 0.77 USP30 (0.49) USP30HDAC1HDAC2PARP1BTK
SCHEMBL25407181 0.75 MAPT (0.40) ALDH1A1MAPTMAPK1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295137-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2023-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295137-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 USP30 809/4885BRD4 1321/4885HDAC1 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback